Checked
Evofem Biosciences, Inc.
OTC: EVFM · Pharmaceutical Preparations · San Diego, CA
- Revenue
- $20.18M
- +4.2% vs. prior year
- Net income
- $391K
- 1.9% net margin
- Total assets
- $20.27M
- Diluted EPS
- $0.00
Company details
As reported to the SEC
- SEC CIK
- 1618835
- Stock
- OTC: EVFM
- Legal Entity Identifier (LEI)
- 5493007VAGG43TIEJW57
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- 12400 High Bluff Drive, Suite 600, San Diego, CA 92130
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (858) 550-1900
- Employer ID (EIN)
- 20-8527075
- Last annual report
- 03/11/2026
- Last quarterly report
- 08/14/2026
Formerly: Neothetics, Inc. (until 01/05/2018)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $20.18M | $19.36M | $18.22M | $16.84M | $8.24M |
| Operating income | $3.37M | -$7.68M | -$17.85M | -$84.12M | -$166.8M |
| Net income | $391K | -$8.86M | $52.98M | -$76.7M | -$205.2M |
| Diluted earnings per share | $0.00 | -$0.11 | $0.05 | -$167.42 | -$23.63 |
| Research and development | Not reported | $1.84M | $2.94M | $25.03M | $33.13M |
| Total assets | $20.27M | $23.79M | $10.55M | $25.16M | $42.51M |
| Total liabilities | $89.71M | $90.26M | $72.47M | $96.96M | $142.1M |
| Shareholders' equity | -$74.34M | -$71.26M | -$66.51M | -$71.8M | -$104.3M |
| Cash and cash equivalents | $578K | $741K | $580K | $2.77M | $7.73M |
| Cash from operations | -$1.99M | -$3.88M | -$8.97M | -$70.41M | -$146.7M |
| Capital expenditures | $5K | $14K | $4K | $341K | $2.94M |
$446K
$8.24M
$16.84M
$18.22M
$19.36M
$20.18M
Subsidiaries
2 companies that Evofem Biosciences, Inc. owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| Biosciences Operations, Inc. | SEC 10-K |
| of Evofem Biosciences, Inc. | SEC 10-K |
Recent filings
137 recent filings on record
Swipe the table sideways to see more columns.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Evofem Biosciences, Inc.'s CIK number?
- Evofem Biosciences, Inc.'s SEC Central Index Key (CIK) is 1618835.
- What is Evofem Biosciences, Inc.'s stock ticker?
- Evofem Biosciences, Inc. trades as OTC: EVFM.
- What was Evofem Biosciences, Inc.'s revenue?
- Evofem Biosciences, Inc. reported revenue of $20.18M for the fiscal year ended Dec 31, 2025, +4.2% from the year before.
- When does Evofem Biosciences, Inc.'s fiscal year end?
- Evofem Biosciences, Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Evofem Biosciences, Inc. headquartered?
- Evofem Biosciences, Inc.'s principal executive office on file with the SEC is in San Diego, CA.
- What companies does Evofem Biosciences, Inc. own?
- Evofem Biosciences, Inc. lists 2 subsidiaries in its SEC filings and other public records, including Biosciences Operations, Inc., of Evofem Biosciences, Inc.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026